|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
|
30677079 |
2019 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
|
30267779 |
2019 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, to comprehensively study the epigenetic landscape, we perform RNA-seq with ChIP-seq for AR and histone modification marks (H3K27ac, H3K4me3, H3K27me3) in 100 primary prostate carcinomas.
|
30464211 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nuclear loss and cytoplasmic expression of androgen receptor in penile carcinomas: role as a driver event and as a prognosis factor.
|
30099587 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, strong AR expression was seen in 73% and in 47% of metastatic breast and urothelial carcinomas, respectively.
|
30293951 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High AR expression was chiefly restricted to a subset of serous carcinomas (50%).
|
28582344 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract.
|
27730305 |
2017 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
|
26890396 |
2016 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Dysregulated androgen receptor (AR) signaling is implicated in several types of tumor, including carcinomas of the prostate, breast, liver and bladder.
|
23715826 |
2013 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Androgen receptor (AR) is a ligand-controlled transcription factor frequently deregulated in prostate carcinomas.
|
19433513 |
2009 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This is similar to the association of alpha-tocopherol-associated protein and androgen receptor expression in normal/benign prostate and prostate carcinomas.
|
19305383 |
2009 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, JMJD2C colocalizes with androgen receptor and LSD1 in normal prostate and in prostate carcinomas.
|
17277772 |
2007 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We suggest that AR gene amplification is an important molecular mechanism underlying the increase in proliferation rate of a substantial fraction of recurrent prostate carcinomas.
|
17217995 |
2007 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results demonstrate that carcinomas resistant to hormonal manipulations still depend on the expression of the androgen receptor for their development in vivo.
|
17925854 |
2007 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Most surprisingly, it has now become clear that prostate carcinomas emerging during the androgen withdrawal therapy (i.e. hormone-refractory tumors) are capable of reactivating the AR-mediated signalling despite of the low levels of androgens.
|
15663988 |
2004 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, we found molecular alterations of AR in more than half of the prostate carcinomas that recurred locally.
|
12429819 |
2002 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Amplification of the androgen receptor gene has been found in a third of hormone refractory prostate carcinomas.
|
11061898 |
2000 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Androgen receptor negative tumours expressed significantly higher amounts of Bcl-2 than those prostate carcinomas with low/medium androgen receptor values.
|
10884916 |
2000 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further characterization of AR mutations will lead to a more thorough understanding of their role in the development of prostate carcinomas.
|
10426191 |
1999 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia.
|
10589774 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The HUMARA assay was applied to 15 gastric carcinomas, early and advanced stage, manifested in superficial, depressed lesions of various sizes and at least some signet ring cells.
|
9731888 |
1998 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Efficacious diagnosis of primary and metastatic human carcinomas with a combination of p53 mutation analysis and clonality analysis of androgen receptor gene.
|
9735408 |
1998 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We recently found amplification of the androgen receptor (AR) gene in approximately 30% of locally recurrent prostate carcinomas from patients treated by conventional androgen deprivation (castration) therapy, whereas none of the untreated primary prostate tumors showed this amplification.
|
9076469 |
1997 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Amplification of the androgen receptor (AR) gene was recently described in recurrent prostate carcinomas from patients who had failed androgen deprivation therapy.
|
9000575 |
1997 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
It is possible that structural changes of the androgen receptor (AR) contribute to the insensitivity of prostatic carcinomas to endocrine therapy.
|
8628719 |
1996 |